Table 1. Evidence for a role of interleukin-17/interleukin-23 in psoriasis
Species |
Evidence |
Reference |
Mouse |
Overexpression of mRNA transcript levels of IL-17A, IL-17F, IL-23p19, and IL-12/IL-23p40 results in inflammatory skin disease |
19,23,24,27[19, 23, 24, 27] |
Injection of IL-17 induced high neutrophilic infiltration in dermis |
[17]17 |
|
Increased number of Th17 (CD4+IL-17+) cells in psoriatic lesions |
[23]23 |
|
Experimentally induced psoriatic lesions abolished by anti-IL-12/23p40 or anti-IL-23p19 antibodies |
19,23,26[19, 23, 26] |
|
IL-23 or the IL-17 receptor deficiency blocked inflammatory disease progression |
[27]27 |
|
Human |
IL-23p19 mRNA and protein is increased in psoriatic lesions |
[30, 106, 107]30,114106,115107 |
Increased number of circulating Th17 (CD4+IL-17+) cells and Tc17 (CD8+IL-17+) in psoriatic patients |
[34, 40, 41]34,40,41 |
|
Increased mRNA and protein expression of IL-17 in psoriatic lesions |
30,36-38,11630,36-38,108[30, 36-38, 108] |
|
Levels of IL-17 correlate with PASI scores and decreased after psoriasis therapy |
[35, 39, 95, 96, 98-101, 103]35, 39, 103, 104, 106-109, 11195,96,98-101,103 |
|
Increased mRNA expression and protein levels of IL-17-induced effector molecules (antimicrobial peptides, cytokines, and neutrophil-attracting CXCL chemokines) in psoriatic lesions |
[44, 51, 52, 109, 110]44,51,52,117,118109,110 |
|
A genetic polymorphism in IL-12/IL-23 p40 is linked to increased susceptibility in psoriasis |
[53, 54, 56]53,54,5657,58,60 |
|
A genetic polymorphism in ACT1 is linked to increased susceptibility in psoriasis |
[63]636763 |
IL- Interleukin; mRNA- messenger RNA; PASI- psoriasis area and severity index